Tipsheet
What matters at India’s listed companies
Earnings · Hospital & Healthcare · Micro cap

Choksi Labs posts 29% profit growth in FY26. Routine results.

Revenue grew 10% to ₹46.22 crore while net profit expanded 29% to ₹1.96 crore. The annual results were anticipated.


Mkt cap₹83.58 cr
P/E42.54×
ROE6.45%
Debt / eq.1.19
₹1.96 cr FY2026 net profit, up 29% year-on-year

What's new

  • FY26 revenue grew about 10% to ₹46.22 crore; net profit rose about 29% to ₹1.96 crore.
  • Q4 performance improved sequentially, with an unmodified audit opinion and no exceptional items.
  • The results are routine and were anticipated.

Why this matters

A 29% profit increase on a 10% revenue gain points to tighter cost control at the nano-cap. But the results were expected and contain no new information. They do not change the investment case.

What we're watching

  • Whether the 29% profit growth rate can be sustained into FY27.
  • Any management commentary on the drivers of the profit expansion.
  • The next quarterly update for signs of acceleration.

The full read

Choksi Laboratories' FY26 results are exactly what a steady nano-cap looks like. Revenue grew 10% to ₹46.22 crore. Profit grew faster, climbing 29% to ₹1.96 crore. The margin expanded. Q4 was better than Q3. The audit is clean. Nothing broke. For a company of this size, that is the point. These numbers confirm the existing trajectory. They do not alter it. The 29% profit growth is solid. The open question is whether it is sustainable, and the filing offers no new clues.

Questions answered

What were the key financial results for Choksi Laboratories in FY26?
Revenue grew about 10% year-on-year to ₹46.22 crore. Net profit grew faster, rising about 29% to ₹1.96 crore.
How did the fourth quarter contribute to the full-year picture?
Q4 improved sequentially, and the filing notes there were no exceptional items in the quarter. The audit opinion is unmodified.
Why is this filing considered routine?
The results are consistent with expectations and do not introduce new material information beyond standard annual reporting.
What does the profit growth outpacing revenue suggest?
It indicates some improvement in profitability, possibly from tighter cost control. The profit margin expanded as net profit grew faster than the top line.
Mentioned: Choksi Laboratories · FY2026 · ₹46.22 cr
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.